28367681|t|Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
28367681|a|Influence of polymorphisms in the genes coding for imatinib transporters and metabolizing enzymes on cytogenetic relapse in patients with chronic myeloid leukemia (CML) is not known. One hundred and four patients (52 cases with cytogenetic relapse and 52 controls without relapse) with chronic-phase CML on imatinib therapy and have completed 5 years of follow-up were enrolled. The following single nucleotide polymorphisms (SNPs) were genotyped; C1236T, C3435T, G2677T / A in MDR1 gene and A6986G in CYP3A5 gene, using PCR-RFLP method and validated by direct gene sequencing. Imatinib trough levels were measured using LC-MS / MS. Patients with CC genotype for MDR1 - C1236T polymorphism were at significantly higher risk for cytogenetic relapse [OR =4.382, 95% CI (1.145, 16.774), p = .022], while those with TT genotype for MDR1 - C3435T polymorphism had significantly lower risk of relapse [OR =0.309, 95% CI (0.134, 0.708), p = .005]. Imatinib trough levels were lower in patients with relapse compared to those without relapse (1551.4 ± 1324.1 vs. 2154.2 ± 1358.3 ng/mL; p = .041). MDR1 - C3435T genotype [adjusted-OR: 0.266; 95% CI (0.111, 0.636); p = .003] and trough levels (p = .014) were independent predictors of relapse in multivariate analysis. To conclude, C1236T and C3435T polymorphisms in MDR1 gene and trough levels significantly influence the risk of cytogenetic relapse. MDR1 - C3435T genotype might emerge as a potential biomarker to predict the risk of cytogenetic relapse in patients with CML.
28367681	3	16	polymorphisms	T045	C0678951
28367681	20	24	MDR1	T028	C0376622
28367681	29	41	CYP3A5 genes	T028	C1413882
28367681	42	51	influence	T077	C4054723
28367681	56	60	risk	T078	C0035647
28367681	64	83	cytogenetic relapse	T191	C0920028
28367681	87	95	patients	T101	C0030705
28367681	101	125	chronic myeloid leukemia	T191	C0023473
28367681	129	137	imatinib	T109,T121	C0935989
28367681	138	145	therapy	T061	C0087111
28367681	147	156	Influence	T077	C4054723
28367681	160	173	polymorphisms	T045	C0678951
28367681	181	193	genes coding	T045	C0314627
28367681	198	206	imatinib	T109,T121	C0935989
28367681	207	219	transporters	T116,T123	C0007292
28367681	224	244	metabolizing enzymes	T116,T126	C0014442
28367681	248	267	cytogenetic relapse	T191	C0920028
28367681	271	279	patients	T101	C0030705
28367681	285	309	chronic myeloid leukemia	T191	C0023473
28367681	311	314	CML	T191	C0023473
28367681	351	359	patients	T101	C0030705
28367681	375	394	cytogenetic relapse	T191	C0920028
28367681	402	410	controls	T096	C0009932
28367681	433	450	chronic-phase CML	T191	C0023473
28367681	454	462	imatinib	T109,T121	C0935989
28367681	463	470	therapy	T061	C0087111
28367681	492	497	years	T079	C0439234
28367681	501	510	follow-up	T058	C1522577
28367681	540	571	single nucleotide polymorphisms	T086	C0752046
28367681	573	577	SNPs	T086	C0752046
28367681	584	593	genotyped	T059	C1285573
28367681	595	601	C1236T	T086	C0314659
28367681	603	609	C3435T	T086	C0314659
28367681	611	617	G2677T	T086	C0314659
28367681	620	621	A	T086	C0314659
28367681	625	634	MDR1 gene	T028	C0376622
28367681	639	645	A6986G	T086	C0314659
28367681	649	660	CYP3A5 gene	T028	C1413882
28367681	668	683	PCR-RFLP method	T059	C3714764
28367681	708	723	gene sequencing	T059	C1294197
28367681	725	733	Imatinib	T109,T121	C0935989
28367681	768	773	LC-MS	T059	C0872318
28367681	776	778	MS	T059	C0037813
28367681	780	788	Patients	T101	C0030705
28367681	794	805	CC genotype	T032	C0017431
28367681	810	814	MDR1	T028	C0376622
28367681	817	823	C1236T	T086	C0314659
28367681	824	836	polymorphism	T045	C0678951
28367681	866	870	risk	T078	C0035647
28367681	875	894	cytogenetic relapse	T191	C0920028
28367681	959	970	TT genotype	T032	C0017431
28367681	975	979	MDR1	T028	C0376622
28367681	982	988	C3435T	T086	C0314659
28367681	989	1001	polymorphism	T045	C0678951
28367681	1026	1030	risk	T078	C0035647
28367681	1034	1041	relapse	T191	C0920028
28367681	1088	1096	Imatinib	T109,T121	C0935989
28367681	1125	1133	patients	T101	C0030705
28367681	1139	1146	relapse	T191	C0920028
28367681	1173	1180	relapse	T191	C0920028
28367681	1236	1240	MDR1	T028	C0376622
28367681	1243	1249	C3435T	T086	C0314659
28367681	1250	1258	genotype	T032	C0017431
28367681	1359	1369	predictors	T078	C2698872
28367681	1373	1380	relapse	T191	C0920028
28367681	1384	1405	multivariate analysis	T081	C0026777
28367681	1420	1426	C1236T	T086	C0314659
28367681	1431	1437	C3435T	T086	C0314659
28367681	1438	1451	polymorphisms	T045	C0678951
28367681	1455	1464	MDR1 gene	T028	C0376622
28367681	1497	1506	influence	T077	C4054723
28367681	1511	1515	risk	T078	C0035647
28367681	1519	1538	cytogenetic relapse	T191	C0920028
28367681	1540	1544	MDR1	T028	C0376622
28367681	1547	1553	C3435T	T086	C0314659
28367681	1554	1562	genotype	T032	C0017431
28367681	1591	1600	biomarker	T201	C0005516
28367681	1616	1620	risk	T078	C0035647
28367681	1624	1643	cytogenetic relapse	T191	C0920028
28367681	1647	1655	patients	T101	C0030705
28367681	1661	1664	CML	T191	C0023473